U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H38O4
Molecular Weight 414.5775
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GESTONORONE CAPROATE

SMILES

[H][C@@]12CC[C@](OC(=O)CCCCC)(C(C)=O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=XURCMZMFZXXQDJ-UKNJCJGYSA-N
InChI=1S/C26H38O4/c1-4-5-6-7-24(29)30-26(17(2)27)15-13-23-22-10-8-18-16-19(28)9-11-20(18)21(22)12-14-25(23,26)3/h16,20-23H,4-15H2,1-3H3/t20-,21+,22+,23-,25-,26-/m0/s1

HIDE SMILES / InChI
Molecular Formula C26H38O4
Molecular Weight 414.5775
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Gestonorone is a progesterone analogue indicated for the treatment of benign prostatic hyperplasia and endometrial cancer. The drug is approved in many countries and used under the names Primostat and Depostat.

Originator

Schering
47

Approval Year

Unknown
139,594

Conditions

ConditionModalityTargetsHighest PhaseProduct
Benign prostatic hyperplasia
28
 Primary
Approved
8,429
PRIMOSTAT
Endometrial cancer
43
 Palliative
Approved
8,429
PRIMOSTAT

PubMed

Patents

WO2015092647 A1
2

Sample Use Guides

In Vivo Use Guide
Slow intramuscular injection of 200 mg every week for 2 to 3 months.
Route of Administration: Intramuscular
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
U38E620NS6
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966